Regulatory clarity and analyst upgrade shift focus back to Intellia’s pipeline

The FDA’s decision to lift clinical holds on Intellia Therapeutics (NTLA) MAGNITUDE and MAGNITUDE-2 trials, after ruling a prior patient death unlikely related to its therapy, has refocused attention on the stock.

At a share price of US$13.55, Intellia has bounced in the near term, with a 1-day share price return of 1.88%, a 7-day return of 5.69% and a 90-day gain of 33.76%. The 1-year total shareholder return of 115.76% contrasts sharply with a 5-year total shareholder return decline of 80.86%, suggesting that momentum has recently rebuilt after a difficult multi year period as investors reassess the risk around its clinical pipeline following the FDA decision and analyst upgrade.

If you are looking beyond Intellia and want more exposure to the theme of AI meeting drug development, this is a good moment to check out 37 healthcare AI stocks

So with Intellia trading at US$13.55, analyst targets sitting higher and the pipeline back in focus, should you see this as a stock trading below its intrinsic value, or is the market already pricing in future growth?

Most Popular Narrative: 46.4% Undervalued

At a last close of $13.55 versus a narrative fair value of $25.29, the widely followed view frames Intellia as significantly undervalued and heavily tied to its late stage gene editing programs.

The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends, especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE, supporting higher future patient volumes and underpinning potential multi-launch revenue inflection points.

Curious what powers that valuation gap? The narrative leans on aggressive revenue build up, margin expansion and a future earnings multiple usually reserved for sector leaders.

Result: Fair Value of $25.29 (UNDERVALUED)

However, this hinges on successful late stage trial execution and real world safety, with competition and reimbursement pushback still capable of flipping the story quickly.

Another angle on valuation: price versus sales

The story changes when you look at the P/S ratio instead of future cash flows. Intellia trades on a P/S of 23.7x, which is higher than the US Biotechs average of 11.2x and also above an estimated fair ratio of 0.1x. This raises the question of whether the market is already paying upfront for a lot of future progress.

Next Steps

Given the mixed signals so far, do you see Intellia’s setup as more opportunity or more risk, and how quickly are you willing to decide after weighing both sides with the 2 key rewards and 2 important warning signs?

Ready to find your next idea?

If Intellia has sharpened your interest in high conviction themes, this is the moment to widen your watchlist and spot opportunities before the crowd catches on.

• Target firms where quality meets potential mispricing by scanning 61 high quality undervalued stocks and see which names stand out on your radar.
• Protect your downside by reviewing companies in the 70 resilient stocks with low risk scores and focus on businesses with steadier risk profiles.
• Hunt for future leaders hiding in plain sight through the screener containing 25 high quality undiscovered gems and see which smaller names could deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.